Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN9A | Q15858 | 6/20 | 0.40 |
| ▸ | GRIN1 | Q05586 | 8/20 | 0.39 |
| ▸ | GRIN2B | Q13224 | 8/20 | 0.39 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.35 |
| ▸ | BRD4 | O60885 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3036262 | 0.83 | GRIN1 (0.40) | GRIN1GRIN2BCACNA1B | |
| SCHEMBL3021050 | 0.82 | GRIN1 (0.37) | GRIN1GRIN2BCACNA1BKCNH2 | |
| SCHEMBL3028107 | 0.79 | ITGB2 (0.42) | GRIN1GRIN2BCACNA1BCYP1A2CYP2C9 | |
| SCHEMBL3033572 | 0.78 | GRIN1 (0.43) | GRIN1GRIN2BCACNA1B | |
| SCHEMBL3042679 | 0.75 | PIK3CA (0.36) | GRIN1GRIN2BCACNA1B | |
| SCHEMBL2804798 | 0.75 | CACNA1B (0.37) | GRIN1GRIN2BCACNA1B | |
| SCHEMBL2786954 | 0.75 | PGR (0.38) | GRIN1GRIN2BCACNA1B | |
| SCHEMBL3033244 | 0.75 | GRIN1 (0.41) | GRIN1GRIN2BCYP1A2CYP2C9CYP2C19 | |
| SCHEMBL8063130 | 0.74 | ITGB2 (0.41) | GRIN1GRIN2BPOLBNPC1 | |
| SCHEMBL3031553 | 0.74 | ITGB2 (0.41) | GRIN1GRIN2BPOLBNPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100204247-A1 | N-SUBSTITUTED OXINDOLINE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS | DUFFY JOSEPH L | 2010-08-12 | — | — | US | claimed |
| EP-2205079-A1 | N-SUBSTITUTED OXINDOLINE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS | Merck Sharp & Dohme Corp. (US) | 2010-07-14 | — | — | EP | claimed |
| WO-2009045381-A1 | N-SUBSTITUTED OXINDOLINE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS | MERCK & CO., INC. (US) | 2009-04-09 | — | — | WO | claimed |
| US-20100204247-A1 | N-SUBSTITUTED OXINDOLINE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS | DUFFY JOSEPH L | 2010-08-12 | — | — | US | disclosed |
| US-20100204247-A1 | N-SUBSTITUTED OXINDOLINE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS | DUFFY JOSEPH L | 2010-08-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100204247-A1 | N-SUBSTITUTED OXINDOLINE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS | CACNA1I, CACNA1D, TRPV1 | SCN9A 246/4885GRIN1 134/4885GRIN2B 109/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.